68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03389451 |
Recruitment Status
:
Enrolling by invitation
First Posted
: January 3, 2018
Last Update Posted
: March 1, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging. If this works, prostate cancer treatments can be prescribed that match the location of the disease. PSMA is radiolabeled with Gallium-68 (Ga-68). This means a participant receives a small dose of radiation from the drug - less than the annual radiation limit for a medical worker.
To test this new drug, participants will receive an injection of Ga-68 PSMA and then have a PET scan. This PET scan, and the reported results, will be entered into the medical record and shared with the treating oncologists.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer Prostatic Neoplasm Prostatic Neoplasms, Castration-Resistant Prostatic Cancer Recurrent Prostatic Cancer Metastatic | Drug: Ga-68 PSMA-HBED-CC PET | Phase 2 Phase 3 |
This study evaluates PSMA-HBED-CC labelled with Gallium-68, abbreviated 68Ga PSMA. This is a radiotracer that attaches to receptors in the membrane of prostate cancer cells. The 68Ga PSMA is identified using a positron emission tomography (PET) scanner. It is believed that 68Ga PSMA will identify prostate cancer more precisely than normal imaging methods (MRI, CT, or ultrasound). Imaging is key to successful treatment - disease must be identified to be treated.
Men who have biochemical recurrence of prostate cancer are invited to test 68Ga PSMA. Participants undergo the 68Ga PSMA PET scan before further treatment. Clinical information, including any MRI, CT, or ultrasound imaging and biopsy/surgery information, will be used to determine if the 68Ga PSMA PET imaging was better than the standard imaging. The study team will collect this information for about 1 year after the PSMA scan.
Depending on findings, participants may be invited back for a second 68Ga PSMA scan. This is done if the first scan showed positive lymph nodes or soft tissue metastases but a surgery or biopsy result does not.
The results from these scans will be shared with the participant. Results will also be entered into the participant's medical record and shared with the treating oncologists.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | 68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence |
Actual Study Start Date : | February 16, 2018 |
Estimated Primary Completion Date : | December 31, 2020 |
Estimated Study Completion Date : | December 31, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: 68Ga PSMA PET scan
Ga-68 PSMA-HBED-CC PET
|
Drug: Ga-68 PSMA-HBED-CC PET
Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
Other Name: Gallium-68 PSMA-HBED-CC PET scan
|
- Determine sensitivity on a per-subject basis of 68Ga PSMA PET scans for detection of tumor location [ Time Frame: Up to 12 months after 68Ga PSMA PET scan ]Sensitivity will be determined on a per-subject basis of 68Ga PSMA PET scan for detection of tumor sites, confirming against imaging, clinical follow-up, and histopathology when available.
- Determine positive predictive value on a per-subject and per-region basis of 68Ga PSMA PET scans for detection of tumor location [ Time Frame: 3 and 12 months after 68Ga PSMA PET scan ]Positive predictive value will be determined on a per-subject basis of 68Ga PSMA PET scan for detection of tumor sites, confirming against imaging, clinical follow-up, and histopathology when available.
- Evaluate adverse events of 68Ga PSMA PET scan [ Time Frame: through 24 hours post-injection of 68Ga PSMA ]Adverse events will be determined through clinical assessment and categorized by CTCAE 4.03

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pathologically proven prostate adenocarcinoma
- Rising PSA after definitive therapy with prostatecomy or radiation therapy (external beam or brachytherapy)
- If post-radical prostatecomy, PSA > 0.2 ng/mL measured > 6 weeks post-operative and confirmed persistent PSA > 0.2 ng/mL (AUA recommendation for biochemical recurrence)
- If post-radiation therapy, PSA that is ≥ 2 mg/mL rise above PSA nadir (ASTRO recommendation for biochemical recurrence)
- Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under an IND for initial efficacy investigations)
- No other malignancy within the past 2 years (skin basal cell or cutaneous superficial squamous cell carcinoma or superficial bladder cancer are exempt from this criterion)
- Karnofsky performance status (KPS) ≥ 50 (ECOG/WHO of 0, 1, or 2)
- Ability to understand and willingness to provide informed consent
Exclusion Criteria:
- Cannot receive furosemide
- History of Stevens Johnson syndrome
- History or diagnosis of Paget's disease
- Malignancy other than current disease under study
- Allergy to sulfa or sulfa-containing medications
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03389451
United States, Iowa | |
The University of Iowa Hospitals & Clinics | |
Iowa City, Iowa, United States, 52242 |
Study Chair: | Michael M. Graham, MD, PhD | The University of Iowa |
Publications:
Responsible Party: | Michael Graham, Professor, University of Iowa |
ClinicalTrials.gov Identifier: | NCT03389451 History of Changes |
Other Study ID Numbers: |
201709730 |
First Posted: | January 3, 2018 Key Record Dates |
Last Update Posted: | March 1, 2018 |
Last Verified: | February 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Codified data will be archived and stored in an imaging repository with limited metadata for analysis. Individuals seeking use of these data should contact the study chair. A data sharing contract for a HIPAA limited dataset will need to be executed prior to data sharing. |
Supporting Materials: |
Clinical Study Report (CSR) |
Time Frame: | Available as requested. Data will be archived indefinitely for research purposes. |
Access Criteria: | Individuals seeking use of these data should contact the study chair. |
Studies a U.S. FDA-regulated Drug Product: | Yes | |
Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Michael Graham, University of Iowa:
68Ga-PSMA-11 (68Ga)Glu-urea-Lys(Ahx)-HBED-CC 68Ga PSMA-HBED-CC |
Additional relevant MeSH terms:
Prostatic Neoplasms Neoplasms Recurrence Prostatic Neoplasms, Castration-Resistant Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Genital Diseases, Male Prostatic Diseases |
Disease Attributes Pathologic Processes N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid Edetic Acid Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action Anticoagulants Calcium Chelating Agents |